With four decades of continuous product development on site, NextPharma’s Asker site, operating as Asker Contract Manufacturing AS, is the group’s centre of excellence for high-volume tablets and chewable tablets, with specialist capabilities in calcium carbonate and vitamin D3 chewables for prescription, OTC and nutritional products.
If you are evaluating a European CDMO for large-scale tablet or chewable production, discover NextPharma Asker’s core capabilities, regulatory status, facility details, and how to start a conversation with the team.
The Asker site has been part of the NextPharma Group since 2023 and has continuously manufactured solid-dose pharmaceuticals since the 1960s. The site is purpose-built to produce high volumes of chewable and conventional tablets.
Our core technology platform is fluid-bed granulation. Batch sizes in blending, compression and packaging can go up to approx. 4 tons handled efficiently using automated material transport and gravity.
We have deep formulation expertise in calcium carbonate and vitamin D3 chewables, in the following core dosage forms:
Flavours are manufactured in-house, supported by lab-scale development equipment and trained internal sensory panel operating to ISO guidelines. Development is integrated into the site: galenical development, analytical development, stability testing, sensory evaluation and CMC documentation are all available, supporting lifecycle management from early formulation through to commercial scale-up.
ICH stability studies and CMC documentation
Product development and analytical services — explore our pharmaceutical development services
Production at NextPharma Asker is conducted in accordance with EU GMP and food supplement requirements. The site operates under Norwegian Medical Products Agency (NOMA) oversight. Our calcium/vitamin D3 portfolio is registered in approximately 50 markets worldwide.
The NextPharma Asker site covers 23,000 m² of built area on a 43,000 m² land plot, with 9,000 m²
dedicated to production and laboratories and 7,500 m² of warehousing (8,000 pallet capacity, with
four automated pallet cranes installed in 2025). We substantially upgraded the production facility
between 2020 and 2025, including a full granulation and primary packaging refresh, a new counting
machine, and an additional tablet press. We have space and capacity to expand with additional lines
for tablet coating and blister packaging. For a full picture of solid dose capabilities across the
network, see our solid dose manufacturing services or the NextPharma locations hub.
Whether it's development, manufacturing or supply. Tell us about your project and our experts will get back to you.
